Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative

Growth Hormone and IGF Research

Volumn 16, Issue SUPPL., 2006, Pages 98-102

  Warren, Michelle P ^a   Chua, Abigail ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Estrogen replacement therapy; Hypopituitarism; Turner syndrome; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GROWTH HORMONE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SEX HORMONE; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; BONE MASS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; ESTROGEN THERAPY; FRACTURE; GONADOTROPIN DEFICIENCY; GROWTH DISORDER; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPOPITUITARISM; MENSTRUAL CYCLE; MORBIDITY; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DEVELOPMENT; SOCIAL PSYCHOLOGY; TREATMENT DURATION; TURNER SYNDROME;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; ESTRADIOL; FEMALE; GROWTH AND DEVELOPMENT; HEALTH PLANNING GUIDELINES; HEALTH PROMOTION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; PSYCHOLOGY; RISK ASSESSMENT; SEXUAL DEVELOPMENT; TURNER SYNDROME;

EID: 33745189406     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.04.003     Document Type: Article

References (32)

1. Sybert V.P., and McCauley E. Turner's syndrome. N. Engl. J. Med. 351 (2004) 1227-1238
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Bonjour J.P., Theintz G., Buchs B., Slosman D., and Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J. Clin. Endocrinol. Metab. 73 (1991) 555-563
4. Even L., Bronstein V., and Hochberg Z. Bone maturation in girls with Turner's syndrome. Eur. J. Endocrinol. 138 (1998) 59-62
5. Landin-Wilhelmsen K., Bryman I., Windh M., and Wilhelmsen L. Osteoporosis and fractures in Turner syndrome - importance of growth promoting and oestrogen therapy. Clin. Endocrinol. (Oxf) 51 (1999) 497-502
6. Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics 102 2 Pt 3 (1998) 481-485
7. Hogler W., Briody J., Moore B., Garnett S., Lu P.W., and Cowell C.T. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J. Clin. Endocrinol. Metab. 89 (2004) 193-199
8. Yigit S. Effect of transdermal versus oral estrogen therapy on achieving near final adult height and near peak bone mass in growth hormone treated adolescents with Turner syndrome. J. Bone Min. Res. 19 (2004) S320 abstract
9. Vestergaard P., Otto J., Jorgensen L., et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case control study. Clin. Endocrinol. 56 (2002) 159-167
10. Klibanski A., Neer R.M., Beitins I.Z., Ridgway E.C., Zervas N.T., and McArthur J.W. Decreased bone density in hyperprolactinemic women. N. Engl. J. Med. 303 (1980) 1511-1514
11. Greenspan S.L., Neer R.M., Ridgway E.C., and Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 104 (1986) 777-782
12. Emans S.J., Grace E., Hoffer F.A., et al. Estrogen deficiency in adolescents and young adults: impact on bone mineral content and effects of estrogen replacement therapy. Obstet. Gynecol. 76 (1990) 585-592
13. Davenport M.L., Punyasavatsut N., Stewart P.W., Gunther D.F., Savendahl L., and Sybert V.P. Growth failure in early life: an important manifestation of Turner syndrome. Horm. Res. 57 (2002) 157-164
14. Gravholt C.H. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur. J. Endocrinol. 151 (2004) 657-687
15. Rosenfield R.L., Devine N., Hunold J.J., Mauras N., Moshang Jr. T., and Root A.W. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 90 (2005) 6424-6430
16. Ross J.L., Long L.M., Skerda M., et al. Effect of low doses of estradiol on 6-month growth rates and predicted height in patients with Turner syndrome. J. Pediatr. 109 (1986) 950-953
17. Vance M.L. Hypopituitarism. N. Engl. J. Med. 330 (1994) 1651-1662
18. Ross J.L., McCauley E., Roeltgen D., et al. Self-concept and behavior in adolescent girls with Turner syndrome: potential estrogen effects. J. Clin. Endocrinol. Metab. 81 (1996) 926-931
19. McCauley E., Feuillan P., Kushner H., and Ross J.L. Psychosocial development in adolescents with Turner syndrome. J. Dev. Behav. Pediatr. 22 (2001) 360-365
20. McCauley E., Ross J.L., Kushner H., and Cutler Jr. G.B. Self-esteem and behavior in girls with Turner syndrome. J. Dev. Behav. Pediatr. 16 (1995) 82-88
21. Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics 101 (1998) E11-E16
22. Gravholt C.H., Naeraa R.W., Nyholm B., et al. Glucose metabolism, lipid metabolism and cardiovascular risk factors in adult Turner syndrome: the impact of sex hormone replacement. Diabetes Care 21 (1998) 1062-1070
23. Price W.H., Clayton J.F., Collyer S., De Mey R., and Wilson J. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. J. Epidemiol. Commun. Health 40 (1986) 97-102
24. Pereira A.M., Schmid E.M., and Schutte P.J. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin. Endocrinol. 62 (2005) 197-204
25. Parker W.H., Broder M.S., Liu Z., Shoupe D., Farquhar C., and Berek J.S. Ovarian conservation at the time of hysterectomy for benign disease. Obstet. Gynecol. 106 (2005) 219-226
26. Manson J.E., Hsia J., Johnson K.C., et al. Women's Health Initiative Investigators, Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349 (2003) 523-534
27. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
28. Gilligan D.M., Quyyumi A.A., and Cannon III R.O. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89 (1994) 2545-2551
29. Anderson G.L., Limacher M., Assaf A.R., et al. The Women's Health Initiative Steering Committee, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
30. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W., and Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N. Engl. J. Med. 31 (1987) 1169-1174
31. Grodstein F., Martinez M.E., Platz E.A., et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann. Intern. Med. 128 (1998) 705-712
32. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727